NewAmsterdam Pharma Co Q3 2026 Results: Net Loss of $17.4M, Loss Narrows
NewAmsterdam Pharma reported a net loss of $130.0 million for the nine months ended September 30, 2026, compared to $128.9 million in the prior year period. Revenue increased significantly to $25.9 million, primarily driven by $19.2 million in the third quarter, while the company maintained a strong liquidity position with $423.1 million in cash and cash equivalents.
- Key figure
- Net loss $17.4M